FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 4, 2013, Pages 598-612

  Kawakami, Masanori ^a   Morita, Shigeki ^a   Sunohara, Mitsuhiro ^a   Amano, Yosuke ^a   Ishikawa, Rie ^a   Watanabe, Kousuke ^a   Hamano, Emi ^a   Ohishi, Nobuya ^a   Nakajima, Jun ^a   Yatomi, Yutaka ^a   Nagase, Takahide ^a   Fukayama, Masashi ^a   Takai, Daiya ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

FER overexpression; Non small cell lung cancer; Prognostic factor

Indexed keywords

PROTEIN TYROSINE KINASE; PROTO ONCOGENE PROTEIN C FES FPS; PROTO-ONCOGENE PROTEIN C-FES-FPS; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; DRUG EFFECT; FEMALE; FER OVEREXPRESSION; FOLLOW UP; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON-SMALL CELL LUNG CANCER; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROGNOSIS; PROGNOSTIC FACTOR; REGRESSION ANALYSIS; SURVIVAL RATE; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

FER OVEREXPRESSION; NON-SMALL CELL LUNG CANCER; PROGNOSTIC FACTOR;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-TYROSINE KINASES; REGRESSION ANALYSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84882751009     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, Honda S and Yamasaki N. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007; 56: 341-348.
4. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I and Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110: 601-605.
5. Okada M, Sakamoto T, Nishio W, Uchino K and Tsubota N. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer 2003; 98: 535-541.
6. Iwasaki A, Shirakusa T, Yoneda S, Makimoto Y, Enatsu S and Hamada T. Results of surgicaltreatment for non-small cell lung cancer of 20 mm or less in diameter. Thorac Cardiovasc Surg 2004; 52: 293-297.
7. Shimizu K, Yoshida J, Nagai K, Nishimura M, Yokose T, Ishii G and Nishiwaki Y. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg 2004; 127: 1574-1578.
8. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, Sugimura H, Pankratz VS and Yang P. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006; 131: 1014-1020.
9. Letwin K, Yee SP and Pawson T. Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using anti-phosphotyrosine antibody. Oncogene 1988; 3: 621-627.
10. Hao QL, Heisterkamp N and Groffen J. Isolation and sequence analysis of a novel human tyrosine kinase gene. Mol Cell Biol 1989; 9: 1587-1593.
11. Ben-Dor I, Bern O, Tennenbaum T and Nir U. Cell cycle-dependent nuclear accumulation of the p94fer tyrosine kinase is regulated by its NH2 terminus and is affected by kinase domain integrity and ATP binding. Cell Growth Differ 1999; 10: 113-129.
12. Kim L and Wong TW. The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors. Mol Cell Biol 1995; 15: 4553-4561.
13. Kim L and Wong TW. Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J Biol Chem 1998; 273: 23542-23548.
14. Rosato R, Veltmaat JM, Groffen J and Heisterkamp N. Involvement of the tyrosine kinase fer in cell adhesion. Mol Cell Biol 1998; 18: 5762-5770.
15. Greer P. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002; 3: 278-289.
16. Craig AW and Greer PA. Fer kinase is required for sustained p38 kinase activation and maximal chemotaxis of activated mast cells. Mol Cell Biol 2002; 22: 6363-6374.
17. Kogata N, Masuda M, Kamioka Y, Yamagishi A, Endo A, Okada M and Mochizuki N. Identification of Fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cells. Mol Biol Cell 2003; 14: 3553-3564.
18. Miravet S, Piedra J, Castano J, Raurell I, Franci C, Dunach M and Garcia de Herreros A. Tyroedsine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Mol Cell Biol 2003; 23: 7391-7402.
19. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A and Dunach M. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 2003; 23: 2287-2297.
20. Allard P, Zoubeidi A, Nguyen LT, Tessier S, Tanguay S, Chevrette M, Aprikian A and Chevalier S. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol Cell Endocrinol 2000; 159: 63-77.
21. Pasder O, Shpungin S, Salem Y, Makovsky A, Vilchick S, Michaeli S, Malovani H and Nir U. Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene 2006; 25: 4194-4206.
22. Condorelli F, Stec-Martyna E, Zaborowska J, Felli L, Gemmi I, Ponassi M and Rosano C. Role of the non-receptor tyrosine kinase fes in cancer. Curr Med Chem 2011; 18: 2913-2920.
23. Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG and Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res 2009; 7: 142-155.
24. Orlovsky K, Theodor L, Malovani H, Chowers Y and Nir U. Gamma interferon down-regulates Fer and induces its association with inactive Stat3 in colon carcinoma cells. Oncogene 2002; 21: 4997-5001.
25. Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y and Liu Y. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer 2009; 9: 366.
26. Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT and Testa JR. A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer 2010; 1: 493-505.
27. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, Lim S, Liu Y, Futreal PA, Grabsch H, Furge KA, Goh LK, Rozen S, Teh BT and Tan P. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2010; 71: 29-39.
28. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours (Uicc InternationalUnion Against Cancer), 6th edn. New York, NY: Wiley-Liss, 2002.
29. Sunohara M, Kawakami M, Kage H, Watanabe K, Emoto N, Nagase T, Ohishi N, and Takai D. Polymerase reaction without primers throughout for the reconstruction of full-length cDNA from products of rapid amplification of cDNA ends (RACE). Biotechnol Lett , 2011, 33, 1301-1307.
30. Matsukura S, Jones PA and Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003; 31: e77.
31. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
32. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H and Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
33. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J and Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
34. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M and Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
35. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y and Mano H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-3149.
36. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH and Seo JS. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-445.
37. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A,Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J and Shibata T. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-377.
38. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Janne PA and Stephens PJ. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18: 382-384.
39. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
40. Paulson R, Jackson J, Immergluck K and Bishop JM. The DFer gene of Drosophila melanogaster encodes two membrane-associated proteins that can both transform vertebrate cells. Oncogene 1997; 14: 641-652.
41. Lilien J, Arregui C, Li H and Balsamo J. The juxtamembrane domain of cadherin regulates integrin-mediated adhesion and neurite outgrowth. J Neurosci Res 1999; 58: 727-734.